Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives

被引：7
|
作者：
Cassese, Gianluca [1 ]
Han, Ho-Seong [2 ,5 ]
Yoon, Yoo-Seok [2 ]
Lee, Jun Suh [2 ]
Lee, Boram [2 ]
Cubisino, Antonio [3 ]
Panaro, Fabrizio [4 ]
Troisi, Roberto Ivan [1 ]
机构：
[1] Federico II Univ Hosp, Dept Clin Med & Surg, Div Minimally Invas HPB Surg & Transplantat Serv, I-80131 Naples, Italy
[2] Seoul Natl Univ, Dept Surg, Coll Med, Seongnam 13620, Gyeonggi Do, South Korea
[3] Beaujon Hosp, Dept HPB Surg & Transplantat, F-92110 Clichy, France
[4] CHU Montpellier, Dept Digest Surg & Liver Transplantat, F-34100 Montpellier, France
[5] Seoul Natl Univ, Dept Surg, Coll Med, 166 Gumi Ro, Seongnam 13620, Gyeonggi Do, South Korea
来源：
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2023年 / 15卷 / 06期
关键词：
Pancreatic cancer; Pancreatic duct adenocarcinoma; Neoadjuvant chemotherapy; Borderline resectable; Locally advanced pancreatic cancer; PHASE-II TRIAL; CIRCULATING TUMOR DNA; GEMCITABINE-BASED CHEMORADIATION; CLINICAL-PRACTICE GUIDELINES; RESECTABLE ADENOCARCINOMA; PREOPERATIVE GEMCITABINE; ADJUVANT CHEMOTHERAPY; COMBINATION THERAPY; IMMEDIATE SURGERY; KRAS MUTATIONS;
D O I：
10.4251/wjgo.v15.i6.911
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pancreatic adenocarcinoma (PDAC) is one of the most common and lethal human cancers worldwide. Surgery followed by adjuvant chemotherapy offers the best chance of a long-term survival for patients with PDAC, although only approximately 20% of the patients have resectable tumors when diagnosed. Neoadjuvant chemotherapy (NACT) is recommended for borderline resectable pancreatic cancer. Several studies have investigated the role of NACT in treating resectable tumors based on the recent advances in PDAC biology, as NACT provides the potential benefit of selecting patients with favorable tumor biology and controls potential micro-metastases in high-risk patients with resectable PDAC. In such challenging cases, new potential tools, such as ct-DNA and molecular targeted therapy, are emerging as novel therapeutic options that may improve old paradigms. This review aims to summarize the current evidence regarding the role of NACT in treating non-metastatic pancreatic cancer while focusing on future perspectives in light of recent evidence.
引用
收藏
页码：911 / 924
页数：14
相关论文
共 50 条
  • [1] Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives
    Gianluca Cassese
    Ho-Seong Han
    Yoo-Seok Yoon
    Jun Suh Lee
    Boram Lee
    Antonio Cubisino
    Fabrizio Panaro
    Roberto Ivan Troisi
    World Journal of Gastrointestinal Oncology, 2023, (06) : 911 - 924
  • [2] Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
    Barroso-Sousa, Romualdo
    Fonseca Reis Silva, Danilo D. A.
    Machado Alessi, Joao Victor
    Mano, Max Senna
    ECANCERMEDICALSCIENCE, 2016, 10
  • [3] Neoadjuvant therapy outcomes in nonmetastatic pancreatic cancer.
    Kovtun, Jeanette Muniz
    Kovtun, Konstantin
    Mortele, Koenraad
    Moser, James
    Bullock, Andrea J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [4] Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review
    Endo, Yutaka
    Kitago, Minoru
    Kitagawa, Yuko
    CANCERS, 2024, 16 (09)
  • [5] Current status and future perspectives on neoadjuvant therapy in gastric cancer
    Sheng Ao
    Yuchen Wang
    Qingzhi Song
    Yingjiang Ye
    Guoqing Lyu
    Chinese Journal of Cancer Research, 2021, 33 (02) : 181 - 192
  • [6] Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
    Blumenthal, Gideon M.
    Bunn, Paul A., Jr.
    Chaft, Jamie E.
    McCoach, Caroline E.
    Perez, Edith A.
    Scagliotti, Giorgio V.
    Carbone, David P.
    Aerts, Hugo J. W. L.
    Aisner, Dara L.
    Bergh, Jonas
    Berry, Donald A.
    Jarkowski, Anthony
    Botwood, Nicholas
    Cross, Darren A. E.
    Diehn, Max
    Drezner, Nicole L.
    Doebele, Robert C.
    Blakely, Collin M.
    Eberhardt, Wilfried E. E.
    Felip, Enriqueta
    Gianni, Luca
    Keller, Steven P.
    Leavey, Patrick J.
    Malik, Shakun
    Pignatti, Francesco
    Prowell, Tatiana M.
    Redman, Mary W.
    Rizvi, Naiyer A.
    Rosell, Rafael
    Rusch, Valerie
    de Ruysscher, Dirk
    Schwartz, Lawrence H.
    Sridhara, Rajeshwari
    Stahel, Rolf A.
    Swisher, Stephen
    Taube, Janis M.
    Travis, William D.
    Keegan, Patricia
    Wiens, Jacinta R.
    Wistuba, Ignacio I.
    Wynes, Murry W.
    Hirsch, Fred R.
    Kris, Mark G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : 1818 - 1831
  • [7] Current status and future perspectives on neoadjuvant therapy in gastric cancer
    Ao, Sheng
    Wang, Yuchen
    Song, Qingzhi
    Ye, Yingjiang
    Lyu, Guoqing
    CHINESE JOURNAL OF CANCER RESEARCH, 2021, 33 (02) : 181 - 191
  • [8] Current and future role of neoadjuvant therapy for breast cancer
    Untch, Michael
    Konecny, Gottfried E.
    Paepke, Stefan
    von Minckwitz, Gunter
    BREAST, 2014, 23 (05): : 526 - 537
  • [9] Diagnostic and Prognostic Role of Extracellular Vesicles in Pancreatic Cancer: Current Evidence and Future Perspectives
    Nicoletti, Alberto
    Negri, Marcantonio
    Paratore, Mattia
    Vitale, Federica
    Ainora, Maria Elena
    Nista, Enrico Celestino
    Gasbarrini, Antonio
    Zocco, Maria Assunta
    Dal Verme, Lorenzo Zileri
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [10] Neoadjuvant therapy for gastric cancer: current evidence and future directions
    Newton, Andrew D.
    Datta, Jashodeep
    Loaiza-Bonilla, Arturo
    Karakousis, Giorgos C.
    Roses, Robert E.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (05) : 534 - 543
12345